OSE Immunotherapeutics — Primed for value appreciation
OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The...
204 Views
OSE Immunotherapeutics — KOL event highlights lusvertikimab’s potential
OSE Immunotherapeutics and Edison held a key opinion leader (KOL) event on 5 March 2025, providing up-to-date insights into OSE’s lead...
75 Views
OSE Immunotherapeutics — Tedopi shows promise in pancreatic cancer
OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with...
82 Views
OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with...
366 Views
OSE Immunotherapeutics - Riding the H124 tailwinds
OSE Immunotherapeutics has reported its results for H124, a standout period for the company’s development pipeline, with the momentum carrying into...
251 Views